Skip to main content

Table 1 Basic information of COPD patients in stable stage

From: Aspergillus fumigatus during COPD exacerbation: a pair-matched retrospective study

  Aspergillus colonization, n = 23 Control, n = 69 p value
Demographics
 Age, yr (IQR) 76 ± 7 75 ± 8 0.741
 Gender (male/female) 20/3 60/9 1.000
 BMI(kg/m2) 22.4 ± 4.1 23.4 ± 3.7 0.266
 Smoking history, n (%) 17 (73.9%) 63 (91.3%) 0.091
 Pack-years (IQR) 58 ± 39 47 ± 36 0.291
COPD characteristics
(post bronchodilators)
 FEV1% (IQR) 40.0 ± 16.0 44.5 ± 16.8 0.261
 GOLD grade
  Grade I 4 (17.4%) 15 (21.7%)  
  Grade II 5 (21.7%) 21 (30.4%)  
  Grade III 12 (54.5%) 30 (51.7%)  
  Grade IV 2 (9.1%) 3 (5.2%)  
 GOLD grade ≥ 3, n (%) 14 (63.6) 33 (56.9) 0.744
Underlying conditions, n (%)
 Hypertension 15 (65.2%) 41 (59.4%) 0.806
 Diabetes mellitus 7 (31.8%) 7 (15.9%) 0.201
 Coronary heart disease 7 (30.4%) 16 (23.2%) 0.580
 Cerebral vascular disease 4 (17.4%) 10 (14.5%) 0.774
 Chronic heart failure 8 (34.8%) 12 (17.4%) 0.089
 Peptic ulcer 0 6 (8.7%) 0.331
 Chronic renal failure 2 (8.7%) 3 (4.4%) 0.597
Stable period treatment
 Corticosteroids use, n (%) 17 (73.9%) 28 (40.6%) 0.008
  daily dose of inhaled corticosteroid >1000μg
(Betamethasone equal dosage)
56.5% 33.3% 0.048
 Long term oxygen therapy 3 (13.0%) 12 (17.4%) 0.753
Times of AECOPD in previous year 1.7 ± 1.3 1.3 ± 1.1 0.186
  1. Italicized p-values are statistically significant, ie. p <0.05